Key Highlights:
- Lupin entered a licensing and supply agreement with Zydus Lifesciences to co-market semaglutide injection (15 mg/3 ml) with a reusable pen device in India, aiming to expand access to advanced therapies for cardio-metabolic disorders.
- Under the deal, Lupin gets semi-exclusive co-marketing rights, launching the therapy as Semanext and Livarise, while Zydus will market it as SEMAGLYN, MASHEMA, and ALTERME; the agreement includes upfront licensing fees and milestone payments.
- A GLP-1 therapy, semaglutide is indicated for type 2 diabetes and chronic weight management, offering a patient-friendly delivery device. The collaboration strengthens both companies’ push to expand access to innovative metabolic treatments across India.
Implications:
The deal lets Lupin plug directly into India’s fast‑building GLP‑1 market without its own development risk, while helping Zydus rapidly widen semaglutide reach through another large cardio‑diabetes field force.
Multiple brands on the same semaglutide backbone will likely accelerate GLP‑1 uptake in both diabetes and obesity clinics, intensifying competition around device convenience, pricing, and patient‑support programs rather than molecule differentiation.
Source: Express Pharma
Other Articles
Next
Previous
No Comment! Be the first one.